Jyong Biotech Ltd. MENS 深 沪
已收盘 05-08 16:00:00 美东时间
2.05
0.000
0.00%
华盛通- 最 高2.1011
- 今 开2.09
- 成交量 3.93万股
- 最 低 2.0008
- 昨 收 2.05
- 总市值 15.59万
- 52周最高 67.00
- 市盈率 静 --
- 换手率 51.69%
- 52周最低 1.43
- 委 比 42.68%
- 总股本 7.60万
- 历史最高 67.00
- 量 比 0.52
- 振 幅 4.89%
- 历史最低 1.43
- 每 手 1
- 风险率 21.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jyong Biotech Delays Annual 20-F (Yearly Report)
Jyong Biotech Ltd. ( ($MENS) ) has released a notification of late filing. Jyon...
04-30 02:19
Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
As previously announced, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its
04-28 20:37
Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states
Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states Jyong Biotech reported updated information on MCS-2, an investigational oral botanical drug candidate being studied for benign prostatic hyperplasia/lower urinary tract symptoms. The company said MCS-2 h
03-27 20:30
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
Jyong Biotech Ltd., a biotechnology company based in Taiwan, has provided updates on MCS-2, an innovative plant-derived drug developed to treat benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). MCS-2 is the first oral botanical drug globally to complete Phase III clinical trials, with data from trials showing excellent safety and no serious adverse events. The company believes MCS-2 addresses the unmet need for a safe, lon...
03-27 12:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
Jyong Biotech Completes Phase II Trial For MCS-8, Expands Commercial Presence In Asia
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial
02-12 21:55
Jyong Biotech Announces Updated Statistical Analyses For Key Blood Biochemical Markers From Phase II Clinical Trial Of MCS-8 Conducted In Taiwan
Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs
01-30 21:45
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Jyong Biotech Ltd. announced updated results from its Phase II clinical trial of MCS-8 (PCP), showing its potential in prostate cancer prevention and reducing high-grade malignancy risk. The trial demonstrated improved lipid control, including a significant reduction in total cholesterol and no increase in LDH levels in the MCS-8 group, suggesting no cell damage. Safety data indicated long-term use did not increase adverse events. The company pla...
01-30 13:30
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
2025-12-31 23:12
美股牛股 | RARE涨超15%，完成向FDA滚动提交生物制品许可申请；FTAI涨超14%
RARE涨超15%，完成向FDA滚动提交生物制品许可申请；FTAI涨超14%，推出数据中心用涡轮发电机FTAI Power；RDW涨超13%，太空概念股获多重利好提振>>
2025-12-31 15:41
